CD19-CAR(Mem) T-cells
Phase 1Biologic
CD19-CAR(Mem) T-cells is one of 4 biologic programs targeting Acute Lymphoblastic Leukemia, in Relapse. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Acute Lymphoblastic Leukemia, in Relapse
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 1
Cytoxan
BBaxter Healthcare Corporation
Phase 1
Mesnex
BBaxter Healthcare Corporation
Phase 1
CD19-CAR(Mem) T-cells
SSt. Jude Children's Research Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD19-CAR(Mem) T-cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details